The FDA has approved the oral substance P/neurokinin-1 (NK-1) receptor antagonist tradipitant ( Nereus – Vanda) for prevention of vomiting induced by motion in adults. Tradipitant is the first drug to be…
Med Lett Drugs Ther. 2026 Jun 22; 68(1757):97-8 doi:10.58347/tml.2026.1757a
The FDA has approved the oral substance P/neurokinin-1 (NK-1) receptor antagonist tradipitant ( Nereus – Vanda) for prevention of vomiting induced by motion in adults. Tradipitant is the first drug to be approved for motion sickness in more than 40 years. Other oral substance P/NK-1 receptor antagonists (i.e., aprepitant, rolapitant, and netupitant) have been available for years for prevention of chemotherapy-induced nausea and vomiting.
Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…
Med Lett Drugs Ther. 2026 Mar 2; 68(1749):33-40 doi:10.58347/tml.2026.1749a
Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into or first appearing in adulthood or even old age. Guidelines for the treatment of AD have recently been updated.
The FDA has approved remibrutinib ( Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H 1…
Med Lett Drugs Ther. 2026 Jan 5; 68(1745):3-6 doi:10.58347/tml.2026.1745b
The FDA has approved remibrutinib ( Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H 1 -antihistamine treatment. Remibrutinib is the first oral drug to be approved in the US for this indication.
The FDA is requiring a new warning in the prescription and over-the-counter labels of the oral second-generation H 1 -antihistamines cetirizine ( Zyrtec , and others) and levocetirizine ( Xyzal , and others)…
Med Lett Drugs Ther. 2025 Aug 18; 67(1735):135 doi:10.58347/tml.2025.1735e
The FDA is requiring a new warning in the prescription and over-the-counter labels of the oral second-generation H 1 -antihistamines cetirizine ( Zyrtec , and others) and levocetirizine ( Xyzal , and others) about the risk of severe pruritus following discontinuation of treatment.
The subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab ( Dupixent – Sanofi/Regeneron) has been approved by the FDA for treatment of chronic spontaneous urticaria in patients ≥12…
Med Lett Drugs Ther. 2025 Jul 7; 67(1732):111-2 doi:10.58347/tml.2025.1732d
The subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab ( Dupixent – Sanofi/Regeneron) has been approved by the FDA for treatment of chronic spontaneous urticaria in patients ≥12 years old who remain symptomatic despite H 1 -antihistamine treatment. Dupilumab was approved earlier for treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease with an eosinophilic phenotype.
Tafasitamab-cxix ( Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated approval from the FDA for use in combination with lenalidomide (Revlimid) for treatment of relapsed or…
Med Lett Drugs Ther. 2023 Aug 7; 65(1682):e133 doi:10.58347/tml.2023.1682d
Tafasitamab-cxix ( Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated approval from the FDA for use in combination with lenalidomide (Revlimid) for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low grade lymphoma, in adults who are not eligible for autologous stem cell transplant. Accelerated approval was based on overall response rates.
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive…
Med Lett Drugs Ther. 2023 Aug 7; 65(1682):121-8 doi:10.58347/tml.2023.1682a
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy.
The FDA has approved Dextenza (Ocular Therapeutix), a dexamethasone ophthalmic insert, for treatment of ocular itching associated with allergic conjunctivitis. Dextenza was approved earlier for treatment of…
Med Lett Drugs Ther. 2023 Mar 20; 65(1672):45-6 doi:10.58347/tml.2023.1672b
The FDA has approved Dextenza (Ocular Therapeutix), a dexamethasone ophthalmic insert, for treatment of ocular itching associated with allergic conjunctivitis. Dextenza was approved earlier for treatment of ocular inflammation and pain following ophthalmic surgery.
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H 1 -antihistamine olopatadine hydrochloride ( Patanase , and generics) and the corticosteroid mometasone furoate (…
Med Lett Drugs Ther. 2023 Jan 23; 65(1668):12-4 doi:10.58347/tml.2023.1668c
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H 1 -antihistamine olopatadine hydrochloride ( Patanase , and generics) and the corticosteroid mometasone furoate ( Nasonex 24 HR Allergy , and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old. Ryaltris is the second intranasal antihistamine/corticosteroid combination to be approved for this indication; azelastine 0.1%/fluticasone propionate ( Dymista , and generics), which is approved for use in persons ≥6 years old, was the first. Both products are available only by prescription.
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training,…
Med Lett Drugs Ther. 2023 Jan 9; 65(1667):1-6 doi:10.58347/tml.2023.1667a
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
The 0.15% nasal spray formulation of the H 1 - antihistamine azelastine hydrochloride ( Astepro Allergy ; Children's Astepro Allergy – Bayer) is now available over the counter (OTC) for temporary relief of…
Med Lett Drugs Ther. 2022 Oct 31; 64(1662):175-6
The 0.15% nasal spray formulation of the H 1 - antihistamine azelastine hydrochloride ( Astepro Allergy ; Children's Astepro Allergy – Bayer) is now available over the counter (OTC) for temporary relief of nasal congestion, runny nose, sneezing, and itchy nose due to allergic rhinitis in adults and children ≥6 years old. It is the first intranasal antihistamine to be approved by the FDA for OTC use. Other drugs that are available OTC for treatment of allergic rhinitis symptoms include oral antihistamines, intranasal corticosteroids, and mast cell stabilizers.
The FDA has approved daridorexant ( Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor…
Med Lett Drugs Ther. 2022 Jul 11; 64(1654):107-10
The FDA has approved daridorexant ( Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
The FDA has approved Acuvue Theravision with Ketotifen (Johnson & Johnson Vision Care), a daily-wear, disposable, vision-correcting soft contact lens that releases the H 1 -antihistamine ketotifen, for…
Med Lett Drugs Ther. 2022 Apr 18; 64(1648):60-1
The FDA has approved Acuvue Theravision with Ketotifen (Johnson & Johnson Vision Care), a daily-wear, disposable, vision-correcting soft contact lens that releases the H 1 -antihistamine ketotifen, for prevention of ocular itch due to allergic conjunctivitis in contact lens users. This is the first approval for a drug-eluting contact lens. Ketotifen eye drops ( Alaway, Zaditor, and others) are available over the counter.
Odevixibat ( Bylvay – Albireo), an oral ileal bile acid transporter (IBAT) inhibitor, has been approved by the FDA for treatment of pruritus in patients ≥3 months old with progressive familial intrahepatic…
Med Lett Drugs Ther. 2022 Feb 21; 64(1644):28
Odevixibat ( Bylvay – Albireo), an oral ileal bile acid transporter (IBAT) inhibitor, has been approved by the FDA for treatment of pruritus in patients ≥3 months old with progressive familial intrahepatic cholestasis (PFIC). It is the first drug to be approved in the US for this indication.
The FDA has approved Apretude (ViiV Healthcare), an IM extended-release (ER) formulation of the integrase strand transfer inhibitor (INSTI) cabotegravir, for use every 2 months to prevent sexually acquired…
Med Lett Drugs Ther. 2022 Feb 21; 64(1644):29-31
The FDA has approved Apretude (ViiV Healthcare), an IM extended-release (ER) formulation of the integrase strand transfer inhibitor (INSTI) cabotegravir, for use every 2 months to prevent sexually acquired HIV-1 infection in at-risk adolescents and adults. Apretude is the first ER formulation to be FDA-approved for pre-exposure prophylaxis (PrEP) of HIV-1 infection.
Difelikefalin ( Korsuva – Vifor), an IV kappa opioid receptor (KOR) agonist, has been approved by the FDA for treatment of moderate to severe pruritus associated with chronic kidney disease (CKD) in adults…
Med Lett Drugs Ther. 2022 Feb 7; 64(1643):18-9
Difelikefalin ( Korsuva – Vifor), an IV kappa opioid receptor (KOR) agonist, has been approved by the FDA for treatment of moderate to severe pruritus associated with chronic kidney disease (CKD) in adults on hemodialysis. It is the first drug to be approved for this indication and the first KOR agonist to become available in the US. Difelikefalin has not been studied in patients on peritoneal dialysis.
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
The FDA has approved lemborexant ( Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be…
Med Lett Drugs Ther. 2020 Jun 29; 62(1601):97-100
The FDA has approved lemborexant ( Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be approved for this indication; suvorexant ( Belsomra ) was the first.
A 0.24% ophthalmic solution of the second-generation H 1 -antihistamine cetirizine ( Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic…
Med Lett Drugs Ther. 2020 Jun 1; 62(1599):81-3
A 0.24% ophthalmic solution of the second-generation H 1 -antihistamine cetirizine ( Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine ( Zyrtec , and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast ( Singulair , and generics) about the risk of suicidal behavior and other serious neuropsychiatric…
Med Lett Drugs Ther. 2020 May 4; 62(1597):65
The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast ( Singulair , and generics) about the risk of suicidal behavior and other serious neuropsychiatric events associated with its use.
Quzyttir (TerSera), an IV formulation of the second-generation H 1 -antihistamine cetirizine, has been approved by the FDA for treatment of acute urticaria in patients ≥6 months old. Oral formulations of…
Med Lett Drugs Ther. 2020 Apr 6; 62(1595):55-6
Quzyttir (TerSera), an IV formulation of the second-generation H 1 -antihistamine cetirizine, has been approved by the FDA for treatment of acute urticaria in patients ≥6 months old. Oral formulations of cetirizine ( Zyrtec , and others) have been for sale over the counter for years. Quzyttir is the first parenteral formulation of a second-generation H 1 -antihistamine to become available in the US; parenteral formulations of two first-generation H 1 -antihistamines, diphenhydramine ( Benadryl , and others) and hydroxyzine ( Vistaril , and others), have been available for many years.
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Oct 7; 61(1582):153-60
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive…
Med Lett Drugs Ther. 2019 Aug 12; 61(1578):121-6
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy. Obsessive-compulsive disorder and posttraumatic stress disorder are now considered separate entities in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); they can also be treated with CBT and many of the same drugs.
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter…
Med Lett Drugs Ther. 2019 Apr 22; 61(1570):57-60
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter (OTC) for relief of symptoms. Prescription products for management of allergic rhinitis and allergic conjunctivitis are reviewed separately.
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.
Med Lett Drugs Ther. 2018 Dec 17; 60(1562):201-5
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.
Acute cough (<3 weeks in duration) generally does not require pharmacologic treatment, especially in children. Suppression of productive cough may be harmful. Management of patients with cough should include…
Med Lett Drugs Ther. 2018 Dec 17; 60(1562):206-8
Acute cough (<3 weeks in duration) generally does not require pharmacologic treatment, especially in children. Suppression of productive cough may be harmful. Management of patients with cough should include elimination of any precipitating factor (e.g., cigarette smoking) and treatment of any underlying cause such as upper airway cough syndrome, gastroesophageal reflux disease, asthma, or other pulmonary disease.
The FDA has approved Odactra (ALK), a sublingual allergen extract, for immunotherapy in adults 18-65 years old with house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis. Odactra is…
Med Lett Drugs Ther. 2018 Feb 26; 60(1541):37-9
The FDA has approved Odactra (ALK), a sublingual allergen extract, for immunotherapy in adults 18-65 years old with house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis. Odactra is the first sublingual allergen extract to be approved in the US for this indication. Three other sublingual allergen extracts were approved earlier (see Table 1).
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation…
Med Lett Drugs Ther. 2017 May 8; 59(1520):71-82
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation H 1 -antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed…
Med Lett Drugs Ther. 2015 Jul 6; 57(1472):95-8
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed here, are also used. Pharmacologic treatment and behavioral therapy are often combined.
Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their…
Med Lett Drugs Ther. 2015 Apr 13; 57(1466):52-8
Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their destination, length of stay, and planned activities were reviewed in a previous issue.
An oral solution ( Vituz – Hawthorne) containing two old drugs, the centrally-acting opioid hydrocodone bitartrate and the first-generation H 1 -antihistamine chlorpheniramine maleate, has been approved by…
Med Lett Drugs Ther. 2013 Nov 25; 55(1430):95-6
An oral solution ( Vituz – Hawthorne) containing two old drugs, the centrally-acting opioid hydrocodone bitartrate and the first-generation H 1 -antihistamine chlorpheniramine maleate, has been approved by the FDA for relief of cough and [other] symptoms associated with upper respiratory allergies or a common cold in adults. Several extended-release products containing hydrocodone and chlorpheniramine are available as capsules and suspensions and have been used for years for similar indications. Vituz is classified as a schedule III controlled substance, but the FDA has asked the DEA to reclassify hydrocodone products as schedule II.
The FDA has approved the over-the-counter (OTC) sale of Nasacort Allergy 24HR (Sanofi), a triamcinolone acetonide nasal spray previously available only by prescription as Nasacort AQ . The OTC product, which…
Med Lett Drugs Ther. 2013 Nov 11; 55(1429):90-1
The FDA has approved the over-the-counter (OTC) sale of Nasacort Allergy 24HR (Sanofi), a triamcinolone acetonide nasal spray previously available only by prescription as Nasacort AQ . The OTC product, which is scheduled to be marketed in the spring of 2014, will be the first corticosteroid nasal spray that can be purchased without a prescription in the US. Nasacort Allergy 24HR is approved for use in patients ≥2 years old with nasal allergy symptoms.
The FDA has approved Diclegis (Duchesnay) , a fixed-dose, delayed-release combination of the H 1 -antihistamine doxylamine and the vitamin B 6 analog pyridoxine, for treatment of nausea and vomiting of…
Med Lett Drugs Ther. 2013 Aug 5; 55(1422):61-2
The FDA has approved Diclegis (Duchesnay) , a fixed-dose, delayed-release combination of the H 1 -antihistamine doxylamine and the vitamin B 6 analog pyridoxine, for treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. It is only available by prescription. Doxylamine and pyridoxine, both currently available over the counter, were previously available by prescription in a fixed-dose combination (Bendectin) for morning sickness. Bendectin was voluntarily withdrawn in the US in 1983 because of claims of teratogenicity that have since been disproven. The combination has continued to be available in Canada as Diclectin .
Omalizumab (Xolair) is a recombinant humanized monoclonal anti-IgE antibody currently approved by the FDA for treatment of moderate to severe persistent allergic asthma. It has been used off-label for…
Med Lett Drugs Ther. 2013 May 27; 55(1417):43-4
Omalizumab (Xolair) is a recombinant humanized monoclonal anti-IgE antibody currently approved by the FDA for treatment of moderate to severe persistent allergic asthma. It has been used off-label for treatment of allergic rhinitis and food allergies. Recently the results of a phase III clinical trial indicated that omalizumab may be effective in treating chronic urticaria as well.
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Treat Guidel Med Lett. 2013 May; 11(129):43-52
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and…
Med Lett Drugs Ther. 2012 Oct 29; 54(1402):85-7
The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H 1 -antihistamine and a corticosteroid.
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications and "natural" remedies. Behavioral changes are often needed as well.
Treat Guidel Med Lett. 2012 Jul; 10(119):57-60
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications and "natural" remedies. Behavioral changes are often needed as well.
Fexofenadine ( Allegra , and others) is the most recent second-generation H 1 -antihistamine to become available over the counter (OTC). Cetirizine ( Zyrtec , and others) and loratadine ( Claritin , and…
Med Lett Drugs Ther. 2011 May 30; 53(1365):41
Fexofenadine ( Allegra , and others) is the most recent second-generation H 1 -antihistamine to become available over the counter (OTC). Cetirizine ( Zyrtec , and others) and loratadine ( Claritin , and others) are already available OTC. Cetirizine can be sedating in usual doses. Loratadine can be sedating in higher-than-usual doses. Fexofenadine remains nonsedating even in higher doses.
Bepotastine besilate 1.5% ophthalmic solution ( Bepreve - ISTA Pharmaceuticals), an H 1 -antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in…
Med Lett Drugs Ther. 2010 Feb 8; 52(1331):11-2
Bepotastine besilate 1.5% ophthalmic solution ( Bepreve - ISTA Pharmaceuticals), an H 1 -antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan.
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (not included here; reviewed in Treatment Guidelines 2008; 6:83 ) are prevalent worldwide, especially in…
Treat Guidel Med Lett. 2010 Feb; 8(90):9-18
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (not included here; reviewed in Treatment Guidelines 2008; 6:83 ) are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control these allergic diseases, patients should be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms. Allergen-specific immunotherapy may be useful for treatment of allergic rhinitis and allergic conjunctivitis, and in preventing severe insect venom-triggered reactions.
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly…
Treat Guidel Med Lett. 2010 Jan; 8(89):1-8
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Cetirizine ( Zyrtec , and others) and cetirizine/pseudoephedrine ( Zyrtec-D ) are becoming available without a prescription this month for treatment of allergic rhinitis and urticaria in adults and children.…
Med Lett Drugs Ther. 2008 Jan 14; 50(1277):1
Cetirizine ( Zyrtec , and others) and cetirizine/pseudoephedrine ( Zyrtec-D ) are becoming available without a prescription this month for treatment of allergic rhinitis and urticaria in adults and children. Cetirizine is the second of the second-generation H1-antihistamines to become available over the counter. Loratadine ( Claritin , and others) was the first. Cetirizine has been shown to be more effective than loratadine in suppressing histamine-induced wheals in healthy volunteers ( W Carey et al. Drugs Exp Clin Res 2002; 28:243 ), but no well-controlled clinical trials have established that any second-generation H1-antihistamine is more effective overall than any other ( M Plaut and MD Valentine. N Engl J Med 2005; 353:1934 ). Cetirizine may be mildly sedating in some patients, but it is significantly less sedating than first-generation H1-antihistamines such as diphenhydramine ( Benadryl , and others) or chlorpheniramine ( Chlor-Trimeton , and others), which have been available without a prescription for many years. Its safety in young children is better documented than that of any other first- or second-generation H1-antihistamine ( Treat Guidel Med Lett 2007; 5:71 ). Download U.S. English
Fluticasone furoate nasal spray ( Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone…
Med Lett Drugs Ther. 2007 Nov 5; 49(1273):90-2
Fluticasone furoate nasal spray ( Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray ( Flonase , and others), which is now available generically.
The physiologic changes that occur with aging can affect the pharmacokinetics and pharmacodynamics of many prescription and over-the-counter drugs, increasing the likelihood of adverse effects.
Med Lett Drugs Ther. 2006 Jan 16; 48(1226):6-7
The physiologic changes that occur with aging can affect the pharmacokinetics and pharmacodynamics of many prescription and over-the-counter drugs, increasing the likelihood of adverse effects.
Montelukast ( Singulair - Merck) is an oral cysteinyl leukotriene D 4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic…
Med Lett Drugs Ther. 2005 Oct 24; 47(1220):87-4
Montelukast ( Singulair - Merck) is an oral cysteinyl leukotriene D 4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic rhinitis and recently for use in perennial allergic rhinitis in adults and children ≥ 6 months old. Intranasal corticosteroids have generally been considered the most effective drugs available for prevention and treatment of allergic rhinitis.
Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn.…
Med Lett Drugs Ther. 2004 Jun 7; 46(1184):45-6
Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn. UVA has been implicated in the development of phototoxicity and photoaging. The FDA permits sunscreen manufacturers to claim broad-spectrum protection if their products block at least part of UVA II in addition to UVB. Click here to view the free full article.
Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the…
Treat Guidel Med Lett. 2004 Jun; 2(22):41-6
Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the blood-brain barrier.
Epinastine HCl, an H 1 -receptor antagonist and mast cell stabilizer, has been approved by the FDA for use in a 0.05% ophthalmic solution ( Elestat - Allergan/Inspire) for prevention of itching associated with…
Med Lett Drugs Ther. 2004 Apr 26; 46(1181):35-6
Epinastine HCl, an H 1 -receptor antagonist and mast cell stabilizer, has been approved by the FDA for use in a 0.05% ophthalmic solution ( Elestat - Allergan/Inspire) for prevention of itching associated with allergic conjunctivitis. The drug is available orally in Europe and Asia.
Montelukast ( Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma ( Treatment Guidelines from The Medical Letter 2002; 1:11 ), has been approved by the FDA for treatment of…
Med Lett Drugs Ther. 2003 Mar 17; 45(1152):21-2
Montelukast ( Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma ( Treatment Guidelines from The Medical Letter 2002; 1:11 ), has been approved by the FDA for treatment of seasonal allergic rhinitis in adults and children more than 2 years old.
The FDA has approved the marketing of loratadine ( Claritin - Schering), a second-generation H 1 -antihistamine, without a prescription. The drug was also recently approved for OTC use as Alavert (Wyeth) and…
Med Lett Drugs Ther. 2003 Jan 6; 45(1147):3-4
The FDA has approved the marketing of loratadine ( Claritin - Schering), a second-generation H 1 -antihistamine, without a prescription. The drug was also recently approved for OTC use as Alavert (Wyeth) and other generics are expected.
Desloratadine (des lor at' a deen; Clarinex - Schering), an active metabolite of the H1-receptor antagonist loratadine ( Claritin ), has been approved by the FDA for oral treatment of allergic rhinitis and…
Med Lett Drugs Ther. 2002 Mar 18; 44(1126):27-8
Desloratadine (des lor at' a deen; Clarinex - Schering), an active metabolite of the H1-receptor antagonist loratadine ( Claritin ), has been approved by the FDA for oral treatment of allergic rhinitis and chronic urticaria in patients at least 12 years old. The patent for loratadine expires in December 2002, and generic or over-the-counter versions are expected.
With the coming of spring, direct-to-consumer (DTC) advertisements in newspapers, in magazines and on television are urging people with seasonal allergies to ask their doctors about one or another of the…
Med Lett Drugs Ther. 2001 Apr 30; 43(1103):35
With the coming of spring, direct-to-consumer (DTC) advertisements in newspapers, in magazines and on television are urging people with seasonal allergies to ask their doctors about one or another of the newer, non-sedating antihistamines.
The number of cough remedies available in the USA continues to multiply, but most products contain the same or similar ingredients in varying combinations. Most acute coughs do not require treatment with…
Med Lett Drugs Ther. 2001 Mar 19; 43(1100):23-5
The number of cough remedies available in the USA continues to multiply, but most products contain the same or similar ingredients in varying combinations. Most acute coughs do not require treatment with drugs, especially in children, and suppression of a productive cough may be harmful.
Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic…
Med Lett Drugs Ther. 2000 Nov 27; 42(1093):111-2
Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic dysfunction, and to have pre-existing cognitive problems that make it difficult to detect the role of drugs causing new symptoms or making old ones worse.
Superseded by Drugs of Choice Handbook Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be…
Med Lett Drugs Ther. 2000 Aug 7; 42(1084):71-2
Superseded by Drugs of Choice Handbook Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective than drugs.
Cetirizine (Zyrtec - Pfizer), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis, perennial allergic rhinitis and chronic…
Med Lett Drugs Ther. 1996 Mar 15; 38(970):21-3
Cetirizine (Zyrtec - Pfizer), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria in adults and children more than 12 years old.
The US Food and Drug Administration has approved the marketing of 5% doxepin hydrochloride cream ( Zonalon - GenDerm) for treatment of pruritus due to eczematous dermatoses. Oral doxepin is used as a tricyclic…
Med Lett Drugs Ther. 1994 Oct 28; 36(934):99-100
The US Food and Drug Administration has approved the marketing of 5% doxepin hydrochloride cream ( Zonalon - GenDerm) for treatment of pruritus due to eczematous dermatoses. Oral doxepin is used as a tricyclic antidepressant ( Sinequan , and others).
Acrivastine/Pseudoephedrine ( Semprex-D ) for Seasonal Allergic Rhinitis (Burroughs-Wellcome), a combination of acrivastine with pseudoephedrine hydrochloride, has been approved by the US Food and Drug…
Med Lett Drugs Ther. 1994 Sep 2; 36(930):78-80
Acrivastine/Pseudoephedrine ( Semprex-D ) for Seasonal Allergic Rhinitis (Burroughs-Wellcome), a combination of acrivastine with pseudoephedrine hydrochloride, has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis. Acrivastine is a new H 1 -receptor antagonist with a chemical structure similar to that of triprolidine ( Actidil , and others) (RN Brogden and D McTavish, Drugs, 41:927, 1991). Pseudoephedrine is an α -adrenergic agonist. The combination is available only by prescription.
A 0.05% ophthalmic solution of levocabastine hydrochloride ( Livostin - Iolab), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic…
Med Lett Drugs Ther. 1994 Apr 15; 36(920):35-6
A 0.05% ophthalmic solution of levocabastine hydrochloride ( Livostin - Iolab), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic conjunctivitis. The new drug is a cyclohexylpiperidine derivative with no structural relationship to any other antihistamine.
Ketorolac (kee' toe role ak) tromethamine 0.5%, a nonsteroidal anti-inflammatory drug (NSAID) previously available for parenteral and oral administration ( Toradol - Medical Letter, 32:79, 1990), has now been…
Med Lett Drugs Ther. 1993 Sep 17; 35(905):88-9
Ketorolac (kee' toe role ak) tromethamine 0.5%, a nonsteroidal anti-inflammatory drug (NSAID) previously available for parenteral and oral administration ( Toradol - Medical Letter, 32:79, 1990), has now been approved for ophthalmic use ( Acular - Allergan, Fisons) to relieve itching in seasonal allergic conjunctivitis. NSAIDs decrease prostaglandin concentrations in the eye, which theoretically might contribute to a decrease in itching. Several other NSAIDs are available for ophthalmic use in the USA, but none is marketed for this indication. Flurbiprofen ( Ocufen ) and suprofen ( Profenal ) are promoted for use in ophthalmic surgery to prevent miosis. Diclofenac ( Voltaren ) is available in an ophthalmic solution for treatment of post-operative inflammation after cataract extraction.
Loratadine ( Claritin - Schering), a new H 1 -receptor antagonist, has been approved by the U.S. Food and Drug Administration for treatment of seasonal allergic rhinitis in patients more than 12 years old. It…
Med Lett Drugs Ther. 1993 Aug 6; 35(902):71-2
Loratadine ( Claritin - Schering), a new H 1 -receptor antagonist, has been approved by the U.S. Food and Drug Administration for treatment of seasonal allergic rhinitis in patients more than 12 years old. It will compete with older, relatively sedating drugs such as chlorpheniramine ( Chlor-Trimeton , and others) and clemastine ( Tavist - Medical Letter, 35:9, 1993) and with newer relatively non-sedating agents such as terfenadine ( Seldane ) and astemizole (Hismanal).
Advertisements for clemastine ( Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter,…
Med Lett Drugs Ther. 1993 Jan 22; 35(888):9-10
Advertisements for clemastine ( Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter, 21:24, 1979) that has now become available without a prescription.
Terfenadine ( Seldane - Marion Merrell Dow) and astemizole ( Hismanal - Janssen) are nonsedating antihistamines widely used to treat symptoms of allergic rhinitis (Medical Letter, 27:65, 1985; 31:43, 1989).…
Med Lett Drugs Ther. 1992 Feb 7; 34(863):9-10
Terfenadine ( Seldane - Marion Merrell Dow) and astemizole ( Hismanal - Janssen) are nonsedating antihistamines widely used to treat symptoms of allergic rhinitis (Medical Letter, 27:65, 1985; 31:43, 1989). Both are available without a prescription in Canada, and the US Food and Drug Administration is apparently considering terfenadine for over-the-counter availability in the USA.
An intranasal formulation of the corticosteroid triamcinolone ( Nasacort - Rh ne- Poulenc Rorer) was recently approved by the US Food and Drug Administration for once-daily treatment of seasonal and perennial…
Med Lett Drugs Ther. 1991 Dec 13; 33(859):116-7
An intranasal formulation of the corticosteroid triamcinolone ( Nasacort - Rh ne- Poulenc Rorer) was recently approved by the US Food and Drug Administration for once-daily treatment of seasonal and perennial allergic rhinitis.
Astemizole ( Hismanal - Janssen), a new antihistamine, was recently marketed in the USA for treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. Like terfenadine ( Seldane - Medical…
Med Lett Drugs Ther. 1989 May 5; 31(792):43-4
Astemizole ( Hismanal - Janssen), a new antihistamine, was recently marketed in the USA for treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. Like terfenadine ( Seldane - Medical Letter, 27:65, 1985), astemizole is claimed to be no more sedating than placebo, but the new drug offers the advantage of a once-daily dosage schedule.
Three benzodiazepines and 16 other compounds are marketed in the USA for treatment of insomnia. Many authorities believe that insomnia is overdiagnosed and overtreated (MK Erman, ed, Sleep Disorders, Psychiatr…
Med Lett Drugs Ther. 1989 Mar 10; 31(787):23-4
Three benzodiazepines and 16 other compounds are marketed in the USA for treatment of insomnia. Many authorities believe that insomnia is overdiagnosed and overtreated (MK Erman, ed, Sleep Disorders, Psychiatr Clin North Am, Volume 10, Dec 1987).
Xerostomia, dry mouth due to decreased or absent saliva, is a common problem, particularly among elderly patients. Decreased salivary flow can be due to many different conditions, including drug therapy, Sj…
Med Lett Drugs Ther. 1988 Jul 29; 30(771):74-6
Xerostomia, dry mouth due to decreased or absent saliva, is a common problem, particularly among elderly patients. Decreased salivary flow can be due to many different conditions, including drug therapy, Sj gren's syndrome (keratoconjunctivitis sicca) or radiation of the salivary glands.